| Mrs Noreen Saher Syed, | |
|
2201 Chapel Ave W, Cherry Hill, NJ 08002-2048 | |
| (856) 488-6500 | |
| Not Available |
| Full Name | Mrs Noreen Saher Syed |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Location | 2201 Chapel Ave W, Cherry Hill, New Jersey |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144912817 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | 26NJ14929800 (New Jersey) | Primary |
| Entity Name | Kennedy Medical Group Practice, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952726796 PECOS PAC ID: 2860616877 Enrollment ID: O20140613000689 |
News Archive
A paper published in the current issue of P&P by a group of researchers of the University of Bologna (headed by Professor Giovanni Fava) and a Harvard psychopharmacologist (professor Ross Baldessarini) has analyzed data that derive from randomized controlled trials concerned with the use of antidepressant drugs in children and adolescents.
Scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed a new approach to alter the function of RNA in living cells by designing molecules that recognize and disable RNA targets. As a proof of principle, in the new study the team designed a molecule that disabled the RNA causing myotonic dystrophy.
InNexus Biotechnology Inc. has announced the United States Food & Drug Administration (FDA) has completed its comprehensive review of the development plans for InNexus' lead preclinical candidate, DXL625 (CD20) for the prospective treatment of Non-Hodgkin's Lymphoma (NHL) and/or Chronic Lymphocytic Leukemia (CLL).
CyDex Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to the company entitled "Sulfoalkyl Ether Cyclodextrin Compositions and Methods of Preparation Thereof." This patent, along with other previously issued technology patents, will provide broader protection for CyDex's Captisol® technology until 2028.
Metabolon, Inc., leaders in global metabolomics, biomarker discovery and biochemical analysis, announced today the grant of US Patent 7,807,138 entitled "Biomarkers of Metabolic Responses to Hepatic Drugs". The USPTO awarded the patent to Metabolon on October 5, 2010. This is the 13th patent issued to Metabolon and the second in its portfolio of biomarker patents.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Noreen Saher Syed, 333 Laurel Oak Rd Ste B, Voorhees, NJ 08043-4453 Ph: (856) 513-4124 | Mrs Noreen Saher Syed, 2201 Chapel Ave W, Cherry Hill, NJ 08002-2048 Ph: (856) 488-6500 |
News Archive
A paper published in the current issue of P&P by a group of researchers of the University of Bologna (headed by Professor Giovanni Fava) and a Harvard psychopharmacologist (professor Ross Baldessarini) has analyzed data that derive from randomized controlled trials concerned with the use of antidepressant drugs in children and adolescents.
Scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed a new approach to alter the function of RNA in living cells by designing molecules that recognize and disable RNA targets. As a proof of principle, in the new study the team designed a molecule that disabled the RNA causing myotonic dystrophy.
InNexus Biotechnology Inc. has announced the United States Food & Drug Administration (FDA) has completed its comprehensive review of the development plans for InNexus' lead preclinical candidate, DXL625 (CD20) for the prospective treatment of Non-Hodgkin's Lymphoma (NHL) and/or Chronic Lymphocytic Leukemia (CLL).
CyDex Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to the company entitled "Sulfoalkyl Ether Cyclodextrin Compositions and Methods of Preparation Thereof." This patent, along with other previously issued technology patents, will provide broader protection for CyDex's Captisol® technology until 2028.
Metabolon, Inc., leaders in global metabolomics, biomarker discovery and biochemical analysis, announced today the grant of US Patent 7,807,138 entitled "Biomarkers of Metabolic Responses to Hepatic Drugs". The USPTO awarded the patent to Metabolon on October 5, 2010. This is the 13th patent issued to Metabolon and the second in its portfolio of biomarker patents.
› Verified 2 days ago
Mary Jo Donnell, NP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1935 Route 70 E, Cherry Hill, NJ 08003 Phone: 856-428-7700 | |
Laura Hamel, APN, WHNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1945 Route 70 E Ste C, Cherry Hill, NJ 08003 Phone: 856-325-3760 Fax: 856-325-3761 | |
Kimberly Borkowski, APN-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1 Brace Rd Ste C1, Cherry Hill, NJ 08034 Phone: 856-428-4100 Fax: 856-428-5748 | |
Mrs. Maria Theresa Morris, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2339 Route 70 W Ste 300, Cherry Hill, NJ 08002 Phone: 856-667-7266 | |
Christina N Carbone, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1865 Marlton Pike E Ste 110, Cherry Hill, NJ 08003 Phone: 215-316-5151 | |
Ms. Lee-ann Halbert, RN, MSN, WHCNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 127 E Partridge Ln, Cherry Hill, NJ 08003 Phone: 856-751-8954 | |
Miss Shelaine Elizabeth Quinn, ACNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 401 Kings Hwy S Ste 5, Cherry Hill, NJ 08034 Phone: 856-428-8992 |